The Journal of Clinical Pathways (11/10, Tumolo) reports researchers found “quality-adjusted progression-free survival (PFS) and time without symptoms or toxicity in women with recurrent ovarian cancer were longer with rucaparib compared with placebo.” The findings were published in the Journal of Clinical Oncology. […]
The ASCO Post (11/4) reports “researchers conducted genetic testing in more than 3,000 patients who were diagnosed with cancer,” and “found that one in eight patients with cancer had an inherited cancer-related gene mutation–and that these mutations would not have been detected in half of these patients if testing had been conducted using a standard guideline-based approach.” […]
Medscape (10/30, Osterweil, Subscription Publication) reported, “Up to 40% of patients with cancer who are treated with bevacizumab develop severe hypertension and renal toxicity,” but researchers have developed a “genetic test performed before treatment” that “could identify patients at highest risk for this potentially life-threatening complication.” The findings were presented “in a plenary session during the […]
Medscape (10/29, Hackethal, Subscription Publication) reports a study published in The BMJ “confirmed that different types of hormone replacement therapy (HRT) are associated with an increased risk for breast cancer and has provided additional information on factors associated with that increased risk.” Yana Vinogradova, PhD, the study’s first author, said, “The study confirms increased risk of breast cancer in […]
Healio (10/7, Demko) reports researchers found after five years of follow-up, “almost half of patients with newly diagnosed BRCA-mutated advanced ovarian cancer were progression-free after receiving 2 years of maintenance olaparib.” The findings were presented at the ESMO Virtual Congress 2020 […]
NBC News (9/30, Stenson) reported researchers found in a large Swedish study that “the HPV vaccine substantially reduces a woman’s risk of developing cervical cancer, especially in women who were immunized at a younger age.” The findings (9/30, Lei) were published in the New England Journal of Medicine. MedPage Today (9/30, Bankhead) reported the researchers found in the study with […]
ctDNA Testing May Provide Sufficient Accuracy For Widespread Adoption In Routine Clinical Practice To Identify Patients With Breast Cancer Suitable For Targeted Therapies Cancer Network (9/17, Slater) reports researchers found in a phase 2a trial “that circulating tumor DNA (ctDNA) testing provides sufficient accuracy for widespread adoption in routine clinical practice to identify patients with breast cancer […]
Medscape (9/10, Fuerst, Subscription Publication) reports all patients with breast cancer “who develop a second primary cancer should undergo multigene panel testing, according to a paper published in JCO Precision Oncology.” The paper’s “authors noted that women with breast cancer have a 4%-16% lifetime risk of a second primary cancer,” but “it hasn’t been clear if […]
Forbes (9/7, Broster) reports that “September marks Gynecological Cancer Awareness Month,” and “according to a new study, 78% of people were unaware of the five different gynecological cancers and 86% didn’t know what symptoms to look out for.” In the study, researchers spoke to 100 women between the ages of 18 and 44, and found “44% […]
Women With Recurrent Ovarian Cancer With Maintenance Use Of Rucaparib May Have Longer Quality-Adjusted PFS And Quality-Adjusted Time Without Symptoms Or Toxicity Compared To Placebo Cancer Therapy Advisor (9/3, Moench) reports researchers conducted an exploratory analysis and found “longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity in women with recurrent ovarian cancer […]